title: Benefit of Patients with an Early and Progressed State of Hepatocellular Carcinoma Treated with Drug-eluting Beads.
abstract: OBJECTIVE
  To evaluate drug-eluting beads (DEB) for transarterial chemoembolization (TACE) in patients with Barcelona Clinic Liver Cancer (BCLC) A to D suffering from hepatocellular carcinoma.
  
  
  METHODS
  The progression-free interval (PFI), survival and laboratory findings of 46 patients were retrospectively analyzed after DEB TACE.
  
  
  RESULTS
  The mean survival interval was 16.93 months. The BCLC A/B group had significantly (p=0.01) longer survival compared to C/D: 20.44 and 10.36 months. Mean PFI was 10.75 months with a significantly (p=0.002) longer PFI of the BCLC A/B group (12.71 months) compared to BCLC C/D (3.91 months). In terms of possible adverse events (AEs) significant changes (p<0.05) were observed in cholinesterase, white blood cells, alkaline phosphatase and C-reactive protein.
  
  
  CONCLUSIONS
  Mean survival and PFI results in the BCLC A/B patient group were comparable to historical controls. In addition, the results suggest that patients with BCLC stage C/D also benefited from DEB TACE.
authors: Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany nils.rathmann@umm.de.
authors: Nils
authors: N
authors: Rathmann
authors: Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
authors: Maliha
authors: M
authors: Sadick
authors: Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
authors: Bjoern
authors: B
authors: Rathmann
authors: Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
authors: Michael
authors: M
authors: Kostrzewa
authors: Department of Biomathematics, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
authors: Christel
authors: C
authors: Weiss
authors: Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
authors: Stefan O
authors: SO
authors: Schoenberg
authors: Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
authors: Steffen J
authors: SJ
authors: Diehl
authors: Department of Internal Medicine II, Division of Gastroenterology and Hepatology, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
authors: Christoph
authors: C
authors: Antoni
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D016461:Chemoembolization, Therapeutic; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage*; D054855:Drug-Eluting Stents; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D004317:Doxorubicin
keywords: BCLC; HKLC; Hepatocellular carcinoma; TACE; tolerance